A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

NCT01353664 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Cancer

Interventions

DRUG: Romidepsin

Sponsor

Celgene

Collaborators

[object Object]